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ABSTRACT 
Background 
Vascular risk factors promote cerebral small vessel disease and neuropathological 
changes, particularly in white matter where large-caliber axons are located. How 
Alzheimer’s pathology influences the brain’s vulnerability in this regard is not well 
understood.  
Objective 
Systemic vascular risk was assessed in relation to cerebrospinal fluid concentrations of 
neurofilament light, a biomarker of large-caliber axonal injury, evaluating for interactions 
by clinical and protein markers of Alzheimer’s disease.  
Methods 
Among Alzheimer’s Disease Neuroimaging Initiative participants with normal cognition 
(n=117), mild cognitive impairment (n=190), and Alzheimer’s disease (n=95), linear 
regression related vascular risk (as measured by the modified Framingham Stroke Risk 
Profile) to neurofilament light, adjusting for age, sex, education, and cognitive diagnosis. 
Interactions were assessed by cognitive diagnosis, and by cerebrospinal fluid markers 
of A42, phosphorylated tau, and total tau. 
Results 
Vascular risk and neurofilament light were not related in the main effect model (p=0.08). 
However, interactions emerged for total tau (p=0.01) and phosphorylated tau (p=0.002) 
reflecting vascular risk becoming more associated with CSF neurofilament light in the 
context of greater concentrations of tau biomarkers. An interaction also emerged for the 
Alzheimer’s disease biomarker profiles (p=0.046) where in comparison to the referent 
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‘normal’ biomarker group, individuals with abnormal levels of both A42 and total tau 
showed stronger associations between vascular risk and neurofilament light.  
Conclusion 
Older adults may be more vulnerable to axonal injury in response to higher vascular risk 
burdens in the context of concomitant Alzheimer’s disease pathology.  
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INTRODUCTION 
Modifiable vascular risk factors, such as systolic hypertension [1], diabetes 
mellitus [2], and smoking [3,4] are associated with an increased incidence of cognitive 
impairment and dementia, likely due to effects on cerebral small vessel disease (SVD) 
contributing to abnormal cognitive aging [5]. Cerebral SVD exists in the majority of 
pathologically-confirmed dementia cases [6] and disrupts network connectivity [7,8], 
conferring cognitive impairment and decline [9]. Longitudinal data from large-scale 
multicenter collaborations (i.e., the Leukoaraiosis and Disability (LADIS) Study) are 
increasingly substantiating the role of cerebral SVD and white matter changes in 
contributing to cognitive and motor declines, depressive symptomatology, and reduction 
of functional autonomy with aging [10], including clinical manifestation of vascular-
related dementia [11]. 
Cerebral SVD is the most common pathology to co-occur with Alzheimer’s 
disease (AD) [12,13], lowers the threshold for clinical expression of AD pathology [14], 
and compromises the efficacy of anti-amyloid therapy [15]. Extant literature has yet to 
fully establish the extent to which AD and SVD confer disparate versus overlapping 
pathological cascades, constituting a critical knowledge gap with important implications 
for identifying effective prevention and treatment targets.  Even if SVD and AD 
represent unique injury pathways, these two disease processes may exacerbate one 
another and compromise the aging brain in a synergistic manner [13].  
Cerebral white matter is particularly vulnerable to ischemic injury from SVD in 
advanced age [16], but little is known about whether co-occurring AD pathology affects 
susceptibility to white matter damage, including axonal injury, in response to vascular 
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risk factors. Animal models of compromised cerebrovascular function suggest ischemia 
promotes diffuse amyloid precursor protein expression [17] and increased A deposition 
[18]. Given that A clearance occurs through vascular-mediated pathways across the 
blood-brain barrier [19] and through interstitial fluid bulk flow between perivascular 
basement membranes [20,21], cerebral SVD may propagate A deposition by 
interfering with the integrity of clearance pathways [22], contributing to worse disease 
trajectory [23,24]. Progressive degeneration of cholinergic cells in AD can also disrupt 
regional cerebral blood flow homeostasis [25,26], increasing susceptibility of the 
cerebral vasculature to damage [27,28]. Overall, vascular risk likely drives cognitive and 
neurodegenerative changes through non-AD pathways [29] but concomitantly 
exacerbates AD-related damage once neural injury exists [30].   
A current limitation in understanding the implications of SVD is that the cerebral 
microvasculature is too small to be clearly visualized in vivo, thus interfering with prompt 
diagnosis and intervention [31]. Accordingly, there is a pressing need to better 
characterize underlying physiological changes related to cerebrovascular disease 
burden and unhealthy brain aging [31]. Neurofilament light (NFL) is a protein polymer 
found in large-caliber myelinated axons. Elevated cerebrospinal fluid (CSF) levels of 
NFL are posited to reflect axonal injury [32] and correlate with white matter damage and 
clinical severity across neurodegenerative diseases [33-35]. Unlike the mechanistically 
heterogeneous nature of white matter hyperintensities observed on magnetic resonance 
imaging (MRI) fluid-attenuated inversion recovery (FLAIR), which correspond to multiple 
structural changes and pathological processes [36], CSF concentrations of NFL allow 
for measurement of axonal injury. Accordingly, CSF NFL offers a means of measuring 
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axonal damage in the aging brain. Given the high prevalence of vascular-related health 
problems among older adults at risk for AD [37], more research is warranted to 
elucidate how burgeoning AD pathology influences the aging brain’s vulnerability to 
vascular-related damage, including axonal injury. This research topic is especially 
clinically relevant given the modifiable nature of most vascular risk factors and paucity 
of promising prevention and treatment targets for AD.  
 In the current study, we assess how vascular risk burden as measured by the 
Framingham Stroke Risk Profile (FSRP) relates to axonal injury as measured by CSF 
NFL in the context of varying degrees of concomitant AD pathology. The FSRP is a 
composite measure of vascular risk burden. Originally designed to predict incidents of 
clinical stroke, FSRP scores also correspond to neuroimaging evidence of cerebral 
SVD, including white matter hyperintensities [38,39] silent cerebral infarcts [40,41], and 
microbleeds [42]. We leveraged the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
cohort, which represents a spectrum from normal cognition (NC), mild cognitive 
impairment (MCI), and clinical AD. In doing so, we are able to (a) test interactions 
between FSRP and cognitive diagnosis to determine whether FSRP and NFL 
associations depend on the presence of clinical symptoms and (b) test interactions 
between FSRP and AD CSF biomarkers (i.e., A42, total tau [t-tau], and phosphorylated 
tau [p-tau]) to determine how associations differ as a function of co-occurring evidence 
of AD. Since co-occurring cerebrovascular disease and AD synergistically confer worse 
clinical outcomes [43,44], we hypothesize that the association between FSRP and CSF 
NFL will be strongest with increased AD pathology defined as presence of abnormal 
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concentrations of AD CSF biomarkers (i.e., A42, t-tau, and p-tau) and clinical evidence 
(i.e., stronger associations across cognitive spectrum from NC to clinical AD).   
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MATERIALS & METHODS 
Participants 
 Participants were drawn from the ADNI, launched in 2003 
(http://adni.loni.usc.edu). The original ADNI study enrolled approximately 800 
participants, aged 55-90 years, excluding major neurological disease (other than AD), 
and history of brain lesion, head trauma, or psychoactive medication use (for full 
inclusion/exclusion criteria, please refer to http://www.adni-info.org). Participants were 
enrolled based on criteria outlined in the ADNI protocol (http://www.adni-
info.org/Scientists). Specifically, NC participants showed no signs of depression, MCI, 
or dementia. Participants with MCI presented with subjective memory concerns and 
impaired performance on Wechsler Memory Scale Logical Memory II in the context of 
preserved daily living activities and no significant levels of impairment in other cognitive 
domains nor signs of dementia. Participants with AD met clinical criteria for dementia 
with a predominantly amnestic profile. Written informed consent was obtained from all 
participants prior to assessments at each site. Analysis of ADNI’s publicly available 
database was approved by our local Institutional Review Board. We accessed publicly 
available data from ADNI on 06/09/2017. For the current study, we included participants 
from the ADNI1 cohort with available baseline CSF biomarker samples and vascular 
risk factor data necessary to calculate the FSRP. 
 
Vascular Risk Burden 
To assess systemic vascular risk burden, we calculated a modified FSRP in the 
ADNI dataset based on baseline visit data. FSRP assigns points by sex for age, systolic 
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blood pressure (accounting for antihypertensive medication usage), history of diabetes, 
current cigarette smoking, prevalent cardiovascular disease (i.e., history of myocardial 
infarction, angina pectoris, coronary insufficiency, intermittent claudication, or heart 
failure), left ventricular hypertrophy, and history of atrial fibrillation [45]. The FSRP 
calculation was modified for the current study by excluding left ventricular hypertrophy 
due to this information being unavailable in ADNI [29,46].  
 
Lumbar Puncture and Biochemical Analyses 
ADNI’s CSF protocol, including collection, processing, and storage procedures, 
have been outlined in detail [47]. We leveraged the master CSF dataset compiled by the 
University of Pennsylvania (UPENNBIOMK_MASTER) and used the first measure of 
A42, t-tau, and p-tau for each participant. CSF NFL levels were quantified by the 
Blennow laboratory in Sweden using a sandwich ELISA method (UmanDiagnostics, 
Umeå, Sweden) following established procedures [48]. The measurements were 
performed by board-certified laboratory technicians who were blinded to clinical data. 
Samples were analyzed in singlicates using one batch of reagents. Analytical variation 
was monitored using internal quality control samples at each plate; intra-batch 
coefficients of variation were below 10%. All samples were in the measureable range.  
 
AD Biomarker Profiles 
 Participants were classified into AD [49] and suspected non-AD pathology 
(SNAP) [50] biomarker profiles according to A and t-tau-defined neurodegeneration 
(ND) status, including biomarker negative (A-/ND-), amyloid positive only (A+/ND-), 
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SNAP (i.e., A-/ND+), and both biomarker positive (A+/ND+). CSF A42 values ≤192 
pg/mL reflected amyloid positivity, and t-tau values ≥93 pg/mL reflected presence of ND 
based on established cutoffs [51].  
 
Experimental Design and Statistical Analysis 
Prior to analyses, six participants were excluded for outlying CSF NFL values 
(defined as >4 standard deviations). For hypothesis testing, linear regression cross-
sectionally related modified FSRP (minus points assigned to age) to CSF NFL 
concentration (pg/mL), adjusting for age, sex, education, and cognitive diagnosis (NC, 
MCI, AD). Next, a series of interaction terms, including (a) FSRP x cognitive diagnosis, 
(b) FSRP x CSF A42, (c) FSRP x CSF t-tau, (d) FSRP x CSF p-tau, and (e) FSRP x AD 
biomarker profile were related to CSF NFL in separate models. For interpretive 
purposes, models were repeated stratifying by cognitive diagnosis, by CSF A42 and 
CSF t-tau using established cutoffs [51], and by AD biomarker profile. Models were not 
stratified by CSF p-tau due to its established cutoff having relatively poor sensitivity and 
specificity in distinguishing AD from NC in the ADNI cohort [51]. Significance was set a 
priori at α=0.05. Analyses were conducted with R version 3.3.1 (http://www.r-
project.org).   
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RESULTS 
Participant Characteristics 
The sample included 402 adults age 54-89 years (74±7 years), including 117 
participants with NC, 190 participants with MCI, and 95 participants with clinical AD. 
CSF NFL ranged from 405 to 5315 pg/mL. CSF A42 ranged from 71 to 300 pg/mL. CSF 
t-tau ranged from 28 to 495 pg/mL. CSF p-tau ranged from 8 to 115 pg/mL. See Table 1 
for participant characteristics by cognitive diagnosis. In this participant sample, CSF 
NFL weakly correlated with p-tau (r=0.14, p<0.0001) and total tau (r=0.23, p<0.0001). 
CSF NFL and A42 were not correlated (p=0.66). 
FSRP and CSF NFL 
See Table 2 for detailed results of main effect, interaction, and stratified 
analyses. Among the whole sample, FSRP appeared modestly related to NFL, but the 
association did not meet the a priori statistical significance threshold (=17.97, p=0.08). 
FSRP did not interact with cognitive diagnosis on NFL levels (F(2,398)=0.30; p=0.74). In 
stratified models, FSRP was unrelated to NFL in each of the three diagnostic groups (p-
values>0.29).  
 FSRP interacted with t-tau (=0.40, p=0.01) and p-tau (=1.67, p=0.002) on CSF 
NFL. In stratified models, FSRP was associated with NFL among t-tau positive 
(=47.57, p=0.002) but not among t-tau negative participants (=-0.96, p=0.94). See 
Fig 1A for illustration. Although the FSRP interaction with amyloid was nonsignificant 
(=-0.25, p=0.18), a similar pattern was observed in stratified analyses whereby FSRP 
was associated with NFL among amyloid positive (=35.17, p=0.006) but not amyloid 
negative participants (=-19.35, p=0.24). See Fig 1B for illustration.  
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Similar to the continuous biomarker interactions, FSRP interacted with AD 
biomarker profile (F(3,389)=2.68; p=0.046). Compared to the A-/ND- referent group, 
the A+/ND+ group differed in the association between FSRP and NFL (=71.3, 
p=0.005). No differences were observed between the referent group and the A+/ND- 
(=42.4, p=0.10) or A-/ND+ (=55.3, p=0.29) groups. In stratified models, FSRP was 
associated with NFL in the A+/ND+ group (=58.74, p=0.002) but not in the A-/ND- 
(=-32.20, p=0.06), A+/ND- (=14.18, p=0.49), or A-/ND+ (=30.18, p=0.39) groups. 
See Fig 2 for illustration.   
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DISCUSSION 
 We evaluated associations between FSRP, a comprehensive index of vascular 
risk, and axonal injury among community-dwelling older adults ranging from cognitively 
normal to clinical dementia, assessing for interactions with cognitive diagnosis and CSF 
measurements of AD pathology. Axonal injury was quantified using CSF NFL, a 
biomarker posited to reflect large-caliber axon damage [52] that is elevated in MCI [48] 
and clinical AD [32] and may explain unique variance in clinical manifestation of AD 
beyond core AD pathology [32]. Within the ADNI cohort, we found the association 
between vascular risk burden and axonal damage appears amplified by the presence of 
AD pathology. Specifically, FSRP interacted with both p-tau and t-tau in a manner 
suggesting that associations with axonal injury became stronger in participants 
commensurate with their extent of neurofibrillary tangle pathology (p-tau) and 
neurodegeneration (t-tau).  A similar interaction also emerged for AD biomarker profile 
wherein compared to the referent ‘normal’ biomarker group, individuals with abnormal 
levels of both A42 (indicating cerebral amyloid deposition) and total tau (indicating 
neurodegeneration) showed stronger associations between vascular risk and axonal 
injury. While FSRP did not interact with A42 on NFL, stratified analyses indicated a 
modest association was present within the amyloid positive group. However, these 
stratified results should be interpreted with caution given the lack of a significant 
interaction effect. 
Older adults may be more vulnerable to axonal injury in response to vascular risk 
burden when neural integrity is already compromised by the cumulative effects of 
mounting AD pathology. It is unlikely that tau pathology on its own directly accounts for 
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the stronger association between vascular risk factors and axonal injury since prior work 
has not consistently supported a link between CSF tau and white matter damage [53], 
including work from our group investigating white matter macrostructure [36] and 
microstructure damage [54]. Like NFL, tau is a cytoskeleton protein, but tau differs from 
NFL in that it promotes microtubule stability and is more abundant in smaller, 
unmyelinated axons localized predominantly in cortical tissue. In contrast, NFL primarily 
serves to increase diameter and conduction velocity of large-caliber, myelinated 
subcortical axons [55,56]. Compared to tau, NFL appears to have more clinical staging 
and prognostic utility across brain diseases involving prominent degradation of white 
matter tracks. For example, CSF concentrations of NFL but not tau differentiate 
between relapsing-remitting and primary progressive types of multiple sclerosis [57]. 
CSF concentrations of NFL but not tau also distinguish clinical Huntington disease 
patients from preclinical gene expansion carrier controls and correlate with 5-year 
probability of disease onset among the gene expansion carriers [58]. While NFL does 
not appear to have disease specificity as a marker of axonal injury, its utility in reflecting 
clinical staging across diseases may convey value as a concomitant biomarker to be 
studied in conjunction with more disease-specific markers of AD. 
The dominant theory of AD pathophysiology posits that biomarkers become 
abnormal in an ordered but temporally overlapping manner. A long asymptomatic phase 
of amyloid aggregation eventually reaches a threshold with subsequent progressive 
neuronal dysfunction and death corresponding to CSF t-tau elevations [59]. Accordingly, 
elevated t-tau and p-tau coupled with increased evidence of amyloid aggregation may 
reflect more advanced AD pathology and neurodegeneration, which could compromise 
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neural resilience to vascular risk burden, resulting in greater vulnerability to axonal 
injury.  
It is noteworthy that cognitive diagnosis did not modify the association between 
FSRP and NFL, suggesting the link between vascular risk burden and axonal injury 
occurs in both asymptomatic and symptomatic individuals. This finding has important 
therapeutic implications, as vascular-related axonal damage in AD may be detectable 
both prior to and throughout the clinical manifestation of symptoms. Future research 
should incorporate longitudinal models to further elucidate how vascular-related axonal 
injury temporally relates to the emergence and progression of AD symptoms.  
Collectively, findings from this study suggest presence of vascular risk factors 
confers a greater likelihood of axonal damage in the context of mounting AD pathology 
and neurodegeneration, regardless of clinical status. These findings should be 
interpreted in the context of certain study limitations. The cross-sectional nature of our 
design limits our ability to draw causal inferences or speculate about temporal ordering 
of pathological changes or whether specific substrates of the AD pathophysiological 
cascade drive the observed associations. Unfortunately, gold-standard MRI FLAIR data 
are unavailable in this particular subset of the ADNI cohort, so white matter 
hyperintensities and other markers of cerebral SVD could not be examined. Other 
limitations to consider when interpreting results include that ADNI participants are 
predominantly non-Hispanic white and well-educated, so findings may not be 
generalizable to more diverse populations. Furthermore, ADNI eligibility criteria 
excluded for overt cerebrovascular disease (i.e., Hachinski score ≤4), so stroke risk and 
cerebrovascular pathology are likely underrepresented in the ADNI sample compared to 
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the general population. Even with this study exclusion, we still observed associations 
between vascular risk burden and axonal injury. We speculate that in a cohort with 
greater vascular risk factors and cerebral SVD, the associations reported here would be 
stronger.  
Despite these limitations, our study has several strengths, including the large, 
well-characterized dataset representing the entire cognitive aging spectrum from 
clinically normal to dementia. This range permitted evaluation of vascular risk and 
axonal injury in the context of preclinical and clinical AD. Additionally, the FSRP 
incorporates multiple vascular risk factors, offering a more comprehensive and 
integrated risk index, as opposed to examining risk factors individually.  
Vascular-related axonal injury represents an important potential target for primary 
prevention and clinical intervention among individuals at high risk for developing AD or 
in the preclinical stages of AD. Whereas there are no current treatments or preventative 
therapies for AD, most vascular health problems are preventable or modifiable in 
nature. Primary prevention and close medical management of vascular health 
conditions should be emphasized to mitigate the clinical progression of AD in older 
adults. Further investigation into mechanisms linking vascular risk factors and axonal 
damage in AD and in non-AD-related abnormal cognitive aging is warranted to examine 
longitudinal associations and identify possible therapeutic targets.  
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Table 1. Participant Characteristics 
 
NC 
n=117 
MCI 
n=190 
AD 
n=95 
p-value 
Age, years 76±5 75±7 75±8 0.28 
Sex, % female 48 33 43 0.03a 
Race, % White Non-Hispanic 91 94 98 0.09 
Education, years 16±3 16±3 15±3 0.06 
APOE-ε4, % carrier 25 55 69 <0.001abc 
Modified FSRP, total* 12.8±3.2 12.3±4.0 12.8±4.2 0.91 
 Systolic blood pressure, mmHg 133±17 134±18 135±15 0.56 
 Anti-hypertensive medication usage, % 54 48 57 0.31 
 Diabetes mellitus, % 5 5 3 0.77 
 Current cigarette smoking, % 39 41 46 0.57 
 Prevalent CVD, % 3 6 4 0.41 
 Atrial fibrillation, % 1 1 0 0.68 
CSF NFL, pg/mL 1120±450 1405±636 1631±764 <0.001abc 
CSF A42, pg/mL 206±55 165±54 144±41 <0.001
abc 
CSF t-tau, pg/mL 70±30 103±61 122±58 <0.001abc 
CSF p-tau, pg/mL 25±15 36±18 41±20 <0.001abc 
Biomarker Group     
 A-/ND-, % 54 24 6 <0.001abc 
 A+/ND-, % 27 31 29 0.79 
 A+/ND+, % 10 43 61 <0.001abc 
 A-/ND+, % 9 2 3 0.02a 
Note. Values denoted as mean±standard deviation or percentage. *Modified FSRP excludes 
points assigned for left ventricular hypertrophy. Modified FSRP minus age points for each 
diagnostic group were NC 5.9±2.8, MCI 5.9±2.9 and AD 6.2±2.7. aNC differed from MCI, 
p<0.05; bMCI differed from AD, p<0.05; cNC differed from AD, p<0.05. AD=Alzheimer’s 
disease; APOE=apolipoprotein E; CSF=cerebrospinal fluid; CVD=cardiovascular disease; 
FSRP=Framingham Stroke Risk Profile; MCI=mild cognitive impairment; NC=normal 
cognition; ND=neurodegeneration; NFL=neurofilament light; p-tau=phosphorylated tau; t-
tau=total tau. 
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Table 2. Main Effect, Interaction, and Sub-group Analyses of FSRP on NFL 
 
  
 
95% Confidence 
Interval 
t-value F-value p-value 
*Covariates +      
FSRP 17.97 -1.93, 37.87 1.78 -- 0.08 
FSRP x diagnosis† -- -- -- 0.30 0.74 
NC 13.58 -12.97, 40.12 1.01 -- 0.31 
MCI 14.85 -14.54, 44.23 1.00 -- 0.32 
AD 28.97 -26.13, 84.07 1.04 -- 0.30 
FSRP x A42 -0.25 -0.62, 0.12 -1.35 -- 0.18 
A42 positive 35.17 10.42, 59.93 2.80 -- 0.006 
A42 negative -19.35 -51.98, 13.27 -1.17 -- 0.24 
FSRP x T-tau 0.40 0.09, 0.71 2.53 -- 0.01 
T-tau positive 47.57 17.23, 77.91 3.10 -- 0.002 
T-tau negative -0.96 -27.87, 25.95 -0.07 -- 0.94 
FSRP x P-tau 1.67 0.59, 2.74 3.05 -- 0.002 
FSRP x Biomarker Group† -- -- -- 2.68 0.046 
A-/ND- -32.20 -65.11, 0.72 -1.94 -- 0.06 
A+/ND- 14.18 -26.72, 55.08 0.69 -- 0.49 
A+/ND+ 58.74 21.30, 96.17 3.12 -- 0.002 
A-/ND+ (SNAP) 30.18 -45.28, 105.65 0.91 -- 0.39 
Note. *Covariates include age, sex, education, and cognitive diagnosis. †ANOVA; all other 
models presented are linear regression analyses. CSF=cerebrospinal fluid; 
FSRP=Framingham Stroke Risk Profile; MCI=mild cognitive impairment; NC=normal 
cognition; ND=neurodegeneration; NFL=neurofilament light; P-tau=phosphorylated tau; 
SNAP=suspected non-AD pathology; T-tau=total tau. 
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Fig 1. FSRP and CSF NFL Stratified by Biomarker Status.  
A. FSRP and CSF NFL by Total Tau Status 
 
B. FSRP and CSF NFL by Amyloid Status 
 
 
Solid lines reflect unadjusted values of CSF NFL concentration (Y axis, pg/mL) 
corresponding to modified FSRP score excluding points assigned for age (X axis). Shading 
reflects 95% confidence interval. Amyloid positive=CSF A42<193 pg/mL; amyloid 
negative=CSF A42≥193 pg/mL; t-tau positive=t-tau≥93 pg/mL; t-tau negative=t-tau<93 
pg/mL; CSF=cerebrospinal fluid, FSRP=Framingham Stroke Risk Profile, 
NFL=neurofilament light, t-tau=total tau. 
Vascular Risk & NFL 
 
 30 
Fig 2. FSRP and CSF NFL by Alzheimer’s Disease and Suspected Non-AD 
Pathophysiology (SNAP) Profile. 
 
 
 
Solid lines reflect unadjusted values of CSF NFL concentration (Y axis, pg/mL) corresponding to 
modified FSRP score excluding points assigned for age (X axis). Shading reflects 95% 
confidence interval; CSF=cerebrospinal fluid, FSRP=Framingham Stroke Risk Profile, 
NFL=neurofilament light. 
 
